Coya Therapeutics stockholders approve 750,000 share increase to equity incentive plan

Coya Therapeutics, Inc.

Amendment to 2021 Equity Incentive Plan adds 750,000 shares, raising total authorized to 2,571,070.
Class II directors elected: Anabella Villalobos, Ph.D. and Dov Goldstein, M.D., M.B.A.
Shareholders ratified Weaver and Tidwell, L.L.P. as independent auditor for FY2024.
All three proposals passed with required votes, including broker non-votes on director and plan items.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Coya Therapeutics, Inc. shareholders approved Election of two Class II directors.

Proposal: director election
Outcome: passed

Exact text from the filing

The election of Anabella Villalobos, Ph.D. and Dov Goldstein, M.D., M.B.A., as Class II directors to hold office for a term of three years, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms. The votes were cast for this matter were as follows: Nominee For Withheld Broker Non-Votes Anabella Villalobos, Ph.D. 4,266,152 1,026,654 1,978,147 Dov Goldstein, M.D., M.B.A. 4,078,787 1,214,019 1,978,147

View on SEC.gov

Browse all shareholder votes →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134376

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.